
Zealand Pharma A/S (Nasdaq: ZEAL) announced the issuance of a Complete Response Letter (CRL) by the U.S. Food and Drug Administration (FDA) for Part 1 of the New Drug Application (NDA) for dasiglucagon. The CRL is linked to deficiencies found during an inspection at a third-party manufacturing facility but not specific to dasiglucagon. No concerns were raised about the drug's clinical data or safety. Zealand aims to address the issues, expecting to resubmit the NDA in the first half 2024.
Like
Save
Share